Factors Affecting Perceptual Threshold in Argus II Retinal Prosthesis Subjects.
OBJECTIVE
The Argus II epiretinal prosthesis has been developed to provide partial restoration of vision to subjects blinded from outer retinal degenerative disease. Participants were surgically implanted with the system in the United States and Europe in a single arm, prospective, multicenter clinical trial. The purpose of this investigation was to determine which factors affect electrical thresholds in order to inform surgical placement of the device.


METHODS
Electrode-retina and electrode-fovea distances were determined using SD-OCT and fundus photography, respectively. Perceptual threshold to electrical stimulation of electrodes was measured using custom developed software, in which current amplitude was varied until the threshold was found. Full field stimulus light threshold was measured using the Espion D-FST test. Relationships between electrical threshold and these three explanatory variables (electrode-retina distance, electrode-fovea distance, and monocular light threshold) were quantified using regression.


RESULTS
Regression analysis showed a significant correlation between electrical threshold and electrode-retina distance (R2= 0.50,P= 0.0002;n= 703 electrodes). 90.3% of electrodes in contact with the macula (n= 207) elicited percepts at charge densities less than 1 mC/cm2/phase. These threshold data also correlated well with ganglion cell density profile (P= 0.03). A weaker, but still significant, inverse correlation was found between light threshold and electrical threshold (R2< 0.52,P= 0.01). Multivariate modeling indicated that electrode-retina distance and light threshold are highly predictive of electrode threshold (R2= 0.87;P< 0.0005).


CONCLUSIONS
Taken together, these results suggest that while light threshold should be used to inform patient selection, macular contact of the array is paramount.


CONCLUSIONS
Reported Argus II clinical study results are in good agreement with prior in vitro and in vivo studies, and support the development of higher-density systems that employ smaller diameter electrodes. (clinicaltrials.gov identifier: NCT00407602).
Second Sight Medical Products, Inc., Sylmar, CA ; Doheny Eye Institute, Keck School of Medicine, Los Angeles, CA.
A K
AK
Ahuja
J
J
Yeoh
J D
JD
Dorn
A
A
Caspi
V
V
Wuyyuru
M J
MJ
McMahon
M S
MS
Humayun
R J
RJ
Greenberg
L
L
Dacruz
retinal degeneration; retinal prosthesis; retinitis pigmentosa